A phase III study (KEYNOTE-024) comparing pembrolizumab monotherapy with platinum-based combination therapy for patients with untreated advanced non-small cell lung cancer (NSCLC), with a PD-L1 tumor proportion score (TPS) ≥ 50%, showed that pembrolizumab monotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to platinum-based combination therapy (4). Here, CD274 is linked to neoplasm.